Trial Profile
Randomized phase II study of docetaxel plus zoledronic acid versus docetaxel in patients with relapsing or refractory non-small cell lung cancer and bone metastasis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2015
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary) ; Docetaxel
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2015 Status changed from recruiting to completed as per the record of University Hospital Medical Information Network - Japan.
- 27 Sep 2011 Results presented at the 2011 European Multidisciplinary Cancer Congress.
- 01 May 2008 New trial record.